GeneTex, Inc.
6.6.2023 15:05:40 CEST | ACCESS Newswire | Press release
IRVINE, CA / ACCESSWIRE / June 6, 2023 / GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform to produce best-in-class biomedical research reagents. The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies. GeneTex has employed this process to develop and thoroughly validate its new programmed death-ligand 1 (PD-L1) recombinant rabbit monoclonal antibody for immunohistochemistry (IHC).
The interaction between PD-L1 (CD274/B7-H1) and its receptor programmed death-1 (PD-1) is not only a focus of cancer immunotherapy research but also has major therapeutic relevance for many solid malignancies. PD-L1 is an immune checkpoint inhibitor that binds to PD-1 expressed on T cells and other effectors to quash immune system overactivation and autoimmunity. Cancer cells exploit this and overexpress PD-L1, creating an immunosuppressive state through induced cell death of anti-tumor T cells. Thus, gauging PD-L1 expression on tumor cells can identify cancers that may respond to anti-PD-L1/PD-1 agents. Given the importance of PD-L1 detection in patient tumor samples for both prognostic and treatment considerations, reliable reagents are clearly essential for both research and clinical decision-making.
Immunohistochemistry is utilized routinely in both academic and clinical settings to determine PD-L1 expression in both normal and cancerous tissues. GeneTex's recombinant rabbit monoclonal antibody (PD-L1 antibody [HL1041]) is a cited, PD-L1-specific, knockout-validated reagent that performs in three applications (i.e., western blot, immunocytochemistry, and IHC). To further evaluate this antibody's IHC capabilities, GeneTex enlisted the assistance of MS Validated Antibodies GmbH (MSVA), a company with demonstrated proficiency in IHC optimization that has assessed over 5000 antibodies for their functionality in formalin-fixed tissue IHC. MSVA completed an extensive analysis of the GeneTex antibody's staining on tumor samples and a broad array of normal tissues, comparing the signal to that of another well-established PD-L1 antibody (see Figure). GeneTex clone [HL1041] exhibited excellent sensitivity and specificity. Marco Sauter, MSVA CEO, commented, "As formalin fixation alters the structure and accessibility of many epitopes, a trustworthy antibody validation for IHC invariably requires the analysis of a very broad range of formalin-fixed tissues. Our analysis of more than 70 different normal tissue types and of a broad range of different cancers exceeds what regulatory agencies currently require. We are gratified that our MSVA approach could help to identify PD-L1 clone [HL1041] with binding properties that are comparable to the most established PD-L1 antibodies on the market."
The need for quality antibodies to visualize the expression of biomarkers crucial for cancer biology research and patient care remains vast, particularly for IHC. GeneTex is presently developing reagents against a number of key targets. Allen Lee, GeneTex's Vice President of Business Development, stressed the importance of expertise-based collaborations to create gold-standard products for scientists and clinicians: "GeneTex is excited to extend our partnership with MSVA. Their IHC validation services align perfectly with GeneTex's core mission, which is to provide the biomedical community with the highest quality immunological reagents supported by extensive research, development, and validation."
GeneTex products are for research use only. Not for diagnostic or therapeutic procedures.
Media Contact:
Allen Lee
Phone: 949.553.1900
Email: allensl@genetex.com
www.genetex.com
Contact Information
Allen Lee
Vice President - Business Development
allensl@genetex.com
(949)553-1900
SOURCE: GeneTex, Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/759287/GeneTex-Launches-PD-L1-Antibody-Comprehensively-Validated-by-MS-Validated-Antibodies-GmbH-for-Immunohistochemistry
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Fermi and TensorWave Agree to Extend Closing Date to October 31, 202622.9.2026 22:01:00 CEST | Press release
DALLAS, TX / ACCESS Newswire / September 22, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced that its wholly owned subsidiary, Fermi Campus 1 LLC, and TensorWave TEX1, LLC ("TensorWave") have signed a First Amendment to their Data Center Lease and Services Agreement (the "Lease"). The amendment extends the closing date under the Lease from September 30, 2026 to October 31, 2026. All other terms of the Lease remain unchanged and in effect. The Lease covers 222 megawatts (MW) of total facility power at Fermi's Project Matador campus and represents approximately $6.5 billion in expected total revenue over its initial 15-year term. Parties Working Constructively Toward Closing The Lease, signed in August 2026, provides that its effectiveness is subject to the satisfaction or waiver of specified closing conditions. Those conditions include executing and delivering related work letters and guaranties; finalizing operations sc
Leggett Dynamics Expands Asia Pacific Headquarters22.9.2026 17:00:00 CEST | Press release
SHANGHAI, CHINA / ACCESS Newswire / September 22, 2026 / Leggett Dynamics today celebrated the grand opening of its expanded Asia Pacific headquarters in Shanghai, China marking the latest investment in the company's growth strategy for the region. The expanded facility includes 40 percent more office space, an innovation showroom and multifunctional space for training, events and enhanced collaboration among customers, suppliers and internal teams. "We're not simply expanding our Asia Pacific headquarters in Shanghai. We're expanding our capability to innovate faster, collaborate more closely and create greater value for our customers. This is critical in a hyper competitive market like China which is redefining the user experience in vehicles and turning comfort and motion into the new battleground globally for brand differentiation," said Marinela Cirstea, President of Leggett Dynamics. Today's grand opening in Shanghai reflects Leggett Dynamics' long-term commitment to Asia Pacific
MicroVision Introduces Advanced Photonics Technology for Next-Generation AI Data Center Scale-Up Architecture22.9.2026 15:20:00 CEST | Press release
REDMOND, WA / ACCESS Newswire / September 22, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception solutions for industrial, security and defense, and automotive applications today announced the introduction by its wholly owned Scantinel subsidiary of an advanced photonics solution designed to address power efficiency and performance challenges critical for next-generation AI data center scale-up architectures and other intelligent infrastructure applications. As the global photonics community gathers in Málaga, Spain this week for the 52nd European Conference on Optical Communication and the Global Photonics Economic Forum, Scantinel revealed its new external laser small form-factor pluggable (ELSFP) module that provides a centralized, serviceable light source for co-packaged optics (CPO) systems in existing and next-generation AI data centers and photonics-enabled AI and cloud infrastructure. Scantinel's differentiated ELSFP technology is built around its core phot
Akkodis and Hamburg Public Transport Association Showcase hvv mia at InnoTrans 2026, Demonstrating the Future of AI-Powered Mobility22.9.2026 06:45:00 CEST | Press release
BERLIN, DE / ACCESS Newswire / September 22, 2026 / Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, will showcase how artificial intelligence is helping transform passenger mobility at InnoTrans 2026, the world's leading international trade fair for transport technology. Headlining Akkodis' presence is hvv mia, one of Akkodis' Synergeticon solutions, developed in collaboration with Hamburg Public Transport Association (hvv) to create more seamless, accessible and connected passenger experiences. Together, Akkodis and hvv will demonstrate how AI can help transportation operators better serve passengers while advancing the digital transformation of rail and other transportation networks. Built on Akkodis' Synergeticon AI Conversational Service Hub, hvv mia is a real-world example of how conversational and agentic AI can connect information, services and transactions across transportation systems through a single natural-language interface. Develop
FQ-42 Vengeance Finds New Home at Creech Air Force Base21.9.2026 17:00:00 CEST | Press release
SAN DIEGO, CA / ACCESS Newswire / September 21, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) congratulates the U.S. Air Force (USAF) on the pace of progress for its Collaborative Combat Aircraft program, which features the FQ-42 Vengeance designed and produced by GA-ASI. The latest milestone took place Sept. 18, when a new FQ-42 Vengeance was delivered to Creech AFB, Nev., to continue operations with test and evaluation units. "The CCA program's rate of progress has been incredible," said Mike Atwood, GA-ASI Vice President of Advanced Programs. "Every week, the Air Force is pushing forward with new and more impressive accomplishments using Vengeance. It's amazing to think of how far this program has come in such a short amount of time." The FQ-42 that arrived at Creech will continue regular test and evaluation operations with the Air Force aimed at experimentation with the new aircraft. Previous efforts with Vengeance and other GA-ASI jets, including XQ-67A Off-Board Sens
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom